Dear vasopressin, where is your place in septic shock?

doi:10.1186/cc2996

Critical Care
Volume 9
Issue 2

Viewing options:

Abstract
Full text
PDF (35KB)

Associated material:

Related literature:

Articles citing this article
on BioMed Central
on Google Scholar
on ISI Web of Science
on PubMed Central
Other articles by authors
on Google Scholar

Duenser MW
Hasibeder WR

on PubMed

Duenser MW
Hasibeder WR
Related articles/pages
on Google

on Google Scholar

on PubMed

Tools:

Post to:

This article is part of a series on Haemodynamics, edited by Claude Martin.

Commentary

Dear vasopressin, where is your place in septic shock?

Martin W Duenser¹ and Walter R Hasibeder²

¹Resident, Division of General and Surgical Intensive Care Medicine, Department of Anesthesiology and Critical Care Medicine, The Medical University of Innsbruck, Austria

²Head, Department of Anesthesiology and Critical Care Medicine, Krankenhaus der Barmherzigen Schwestern, Ried im Innkreis, Austria

author email corresponding author email

Critical Care 2005, 9:134-135doi:10.1186/cc2996


Published:	15 November 2004

See related review article http://ccforum.com/content/9/2/212

Abstract

Cardiovascular failure is one of the central therapeutic problems in patients with severe infection. Although norepinephrine is a potent and, in most cases, highly effective vasopressor agent, very high dosages leading to significant side effects can be necessary to stabilize advanced shock. As a supplementary vasopressor, arginine vasopressin can reverse hemodynamic failure and significantly decrease norepinephrine dosages. Whether the promising possibility of 'bridging' advanced septic shock when the benefit/risk ratio of catecholamine therapy leaves a clinically tolerable range may improve quantitative and qualitative patient outcome can only be determined by a large, prospective, randomized study.